# Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

> **NCT05266586** · PHASE2 · COMPLETED · sponsor: **NewAmsterdam Pharma** · enrollment: 119 (actual)

## Conditions studied

- Dyslipidemias
- High Cholesterol
- Hypercholesterolemia

## Interventions

- **DRUG:** Obicetrapib
- **DRUG:** Ezetimibe 10mg
- **OTHER:** Obicetrapib placebo
- **OTHER:** Ezetimibe placebo

## Key facts

- **NCT ID:** NCT05266586
- **Lead sponsor:** NewAmsterdam Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-09
- **Primary completion:** 2022-08-12
- **Final completion:** 2022-09-08
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266586, "Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05266586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*